Abstract: A gain control part controls a gain varying part such that the gain of a received signal corresponds to the input level of the received signal in a first control mode and controls the gain varying part so as to fix the gain of the received signal in a second control mode. A setting part sets the gain control part in the first control mode in a communication state and sets the gain control part in the second control mode in a standby mode.

Abstract: The present invention relates to a high affinity monoclonal antibody for human G-CSF and to an enzyme immunoassay using said antibody. Specifically, the practice of the invention permits one skilled in the art to obtain monoclonal antibodies with the characteristics necessary to permit low-level detection of G-CSF in plasma of equal to or less than 0.5 pg/ml in an immunoassay without interference in human fluids.

Abstract: A semiconductor integrated circuit comprises a signal input terminal, a power supply voltage terminal to which a power voltage is applied, a reference voltage terminal to which a ground voltage is applied, a first PMOS transistor having a drain, a gate connected to the signal input terminal, and a source connected to the power supply voltage terminal, a second PMOS transistor having a gate and a drain being mutually connected to each other, and a source connected to the drain of the first transistor, a third PMOS transistor having a gate connected to the drain of the second transistor, a source connected to the power supply potential terminal, and a drain connected to the drain of the first transistor, an NMOS transistor having a gate connected to the power supply voltage terminal, a drain connected to the drain of the second PMOS transistor, and a source connected to the reference voltage terminal, an internal circuit connected to the drain of the NMOS transistor, a first overvoltage absorption element, conn

Abstract: The present invention relates to a high affinity monoclonal antibody and to an enzyme immunoassay of human G-CSF using the antibody.The trace amount of human G-CSF in samples such as body fluids from patients with hematological disorders can be measured without interference in the body fluids. For example, the measurable human G-CSF concentration in plasma is 0.5 pg/ml in minimum.

Abstract: A physiologically active polysaccharide is prepared by treating autolysis-insoluble matters of yeasts of Saccharomyces with a yeast cell wall-lytic enzyme and obtaining a water-soluble physiologically active substance in the resulting solution-fraction. The novel polysaccharide possesses specific physical and chemical properties, and provides a chemotherapeutic agent such as a carcinostatic agent which can be used in the treatment of implanted tumors in mice and rats and an interferon inducer.